Sign in to view content

Avacincaptad Pegol, A Novel C5 Inhibitor, Reached Statistical Significance in a Pivotal Clinical Trial for Geographic Atrophy Secondary to Dry AMD

Baruch D. Kuppermann, MD, PhD

Video
Published 2020

Related

Learnings From the Lampalizumab Chroma and Spectri Phase 3 Trials: Effect of Baseline Characteristics on Geographic Atrophy Progression
Carl D. Regillo, MD
Annual Meeting Talks
2018
Episode 9: Rate of Macular Atrophy in HARBOR Study with Dr. SriniVas Sadda
Keyvan Koushan, MD, FRCSC
Member Podcasts
2018
Evaluation of Baseline Characteristics on Lesion Progression in a Large Phase 2 Clinical Trial for Geographic Atrophy (FILLY Study)
Eleonora Lad, MD, PhD
Annual Meeting Talks
2019

Category: AMD-Neovascular

See more